I would not hang my hat on 853, or any IMGN drug until they are proven in a phase II. The initial phase I data for 853 were not very exciting. Better dosing selection might help a little. BTW, for the poster who credited Charlie for implementing target testing, I sent them info on the ECYT FOLR1 Imgaing agent and pounded execs and the BOD for their poor 25 year phase II track record of failure.
I hope for shareholders that one day they do something good, but I have seen nothing to indicate they will. TDM1 is effective and the Sanofi naked antibody seems to be a potential winner, but the dopes running IMGN gave them both away. Step 1 is get Junius out, step 2 is clean out the rest of the dead wood, something they should have done after the 901 debacle. Junius seems to own the BOD, or they are too stupid, or lazy to make the difficult decisions.
what's this "great news" was anything specifically mentioned regarding Belviq sales #'s, or is this just conjecture.
loser basher working out of the hedge fund closet making $.01 a post and another .01 for a response. We just provided for it.
I had owned 20,000-30,000 shares for the past several years until recently. I've followed the company off and on since 1990-91. But go right ahead, you know more.
It's hard to believe people are still buying their BS. 289 was promoted as the next great thing, "the naked antibody better than Rituxan in pre-clinical trials". Apparently the developer was exaggerating and the CEO is too ignorant to know the difference.
At least IMGN finally hired a competent sr. exec. They should promote Richard Gregory and then totally clean house. Almost all of the sr. execs have no credibility and the BOD is worthless. If 853 results are not significantly positive, this stock is going back to $5-6 in 5 weeks. I would take a look back at the early 853 results, they were not exciting. Unless they "figured something out" that makes the drug more effective, either better pt. targeting or dosing, or both, expect more of the same.
They should ask Sanofi for the other drug back (naked antibody), that one looks the most promising and Sanofi is doing nothing with it.
Junius is still dreaming of running a fully integrated bio-pharma??? He has no credibility. Buy some shares Dan!
weren't they supposed to have additional pipeline updates by now? Bel numbers were decent, pipeline developments are overdue. The clock is ticking on CEO's promise that the pipeline will become more valuable in 2015. Show us the $ JL.
ARNA factory should produce ACAD's drug when approved. ACAD needs mfg help, the products are similar. It's a good rev opportunity that I brought to their attention about a year ago.
agree and agree although in the low $20's not quite as well/ Looks like a nice V over to my right. If $24 is broken, shorts will not sleep well.
clearly the priest forgot to tell him "sin no more" and thou shalt not steal or tell a lie, or not to covet thy neighbors stock, or kill shareholder value, or not to be greedy...
God please reward the patience of the long suffering shareholders of this forsaken company. Please help us to remove the do-nothing BOD and other hangers-on that are sucking the life and funds out of this company! That's my prayer for the shareholders.
it's shorts + failure of management (mainly Jack and the Bean counter) to create confidence due to insider selling, poor communications, past mistakes, dilution/bad deals with DF. One day soon I hope they will create an opportunity to sell high.
No mention of their 5 rating from basher Z? That's usually why they write these articles. This one appeart to have some real content?
great info, thanks. I follow biotech stocks and hate the lack of timely information on clinical trial enrollment, sales date, etc. Love the transparency and exec management at EXAS. 30MM shares short now. Shorts love scare shareholders with fear and uncertainty. This added info reduces uncertainty.
ARNA has an interesting pipeline and is on sale due to heavy short selling. Some smart biotech firm with drug development talent/expertise can certainly make one, or more of their pipeline products work.